Risk Factors and Multiomics Study of Chronic Kidney Disease Caused by Metabolic Diseases
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Biomarkers.
- Who it may be relevant to
- Registry conditions: Chronic Kidney Diseases, Hypertension, Diabetes Mellitus, Hyperuricemia. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
With the development of China's economy, people's living standard have improved, and the dietary structure have changed. Metabolic diseases, such as hypertension, diabetes, hyperuricemia and obesity have gradually become an important health burden in China. The pathophysiological mechanism of renal injury caused by metabolic diseases has always been a hotspot of research. Currently, it is believed that various mechanisms including the activation of Renin-Angiotensin-Aldosterone System, vascular endothelial dysfunction, oxidative stress and inflammatory process may be involved. Although there are differences in renal pathological manifestations caused by different metabolic diseases, the kidney will eventually present ischemic changes and fibrosis with the progression of the disease. So there must be some common pathogenesis. This study is designed to build a disease cohort of patients with chronic kidney disease caused by metabolic diseases, to identify risk factors leading to disease progression and to explore biomarkers for early diagnosis and treatment of kidney damage.
Interventions
- Diagnostic test Biomarkers
Blood,urine and imaging biomarkers for early diagnosis and prediction of prognosis.
Primary outcome measures
- Number of Participants with End Stage Renal Disease [Time frame: 3 years]
- Number of Participants with Adverse cardiovascular events [Time frame: 3 years]
- Number of Participants with all cause death [Time frame: 3 years]
Secondary outcome measures (4)
- Number of Participants with eGFR decline [Time frame: 3 years]
- Number of Participants with Complications of CKD [Time frame: 3 years]
- Life quality assessment with short form-36 (SF-36) [Time frame: 3 years]
- Advanced Intelligence Assessment with Mini-Mental State Examination (MMSE) [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- The diagnosis of metabolic diseases were confirmed;
- Be able to understand the process of the research;
- Volunteer for participation and be able to sign the informed consent.
Exclusion criteria
- Age <18 yrs or >80yrs;
- Patients with primary and secondary glomerular diseases
- Patients with other comorbidities that could affect the volume or the components of the kidney, such as renal cysts, polycystic kidney disease, medullary sponge kidney, hydronephrosis, renal artery stenosis, renal vein thrombosis and/or renal tumors;
- Contraindications for MRI examination;
- Pregnant or lactation patients;
- Patients with unstable vital signs, failure of other organs or dysphoria.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Peking Union Medical College Hospital — Beijing
Identifiers
NCT: NCT05476627 · JS-2136